BIOCON LTD. - 532523 - Board Meeting Outcome for Outcome Of Board Meeting
The Board has considered the following: 1. Approved the un-audited financial results (standalone and consolidated)for the quarter ended June 30, 2022 2. Completion of tenure of Independent Directors namely Ms. Mary Harney (DIN: 05321964) and Mr. Daniel M Bradbury (DIN: 06599933), The Board Meeting commenced at 4:30 p.m. and concluded at 6:45 p.m. BIOCON LTD. - 532523 - Financial Results For The Quarter Ended June 30, 2022
Financial results: Approved the un-audited financial results (standalone and consolidated) of the Company prepared as per Indian Accounting Standard (Ind-AS) along with Limited Review Report thereon for the quarter ended June 30, 2022. A copy of the un-audited financial results along with the Limited Review Report is enclosed herewith.
Biocon receives three US FDA observations on its Telangana plant
Biotechnology major Biocon on Thursday said the US health regulator has issued three observations after inspecting its Telangana-based manufacturing plant. The US Food and Drug Administration (USFDA) concluded a pre-approval inspection for Site 3 located at Hyderabad on July 20, Biocon Ltd said in a regulatory filing. "Three observations were cited at the end of the inspection, which we will be addressing within the stipulated time," it added. The company stands committed to quality, safety and efficacy of its products, the Bengaluru-based company said. BIOCON LTD. - 532523 - Notification
'US FDA concluded a pre-approval inspection for Site 3, Biocon Limited, located at Hyderabad, Telangana on 20 July 2022. Three observations were cited at the end of the Inspection, which we will be addressing within the stipulated time. Biocon stands committed to the Quality, Safety & Efficacy of its products.' BIOCON LTD. - 532523 - Statement Of Investor Complaints For The Quarter Ended June 2022
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 118190 Name of the Signatory :- Mayank VermaDesignation :- Company Secretary and Compliance Officer BIOCON LTD. - 532523 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
This is to certify that the details of securities dematerialized and rematerialized during the quarter ended June 30, 2022, as required under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018 have been furnished to all the Stock Exchanges where the shares of Biocon Limited are listed. The certificate from our RTA i.e. M/s. KFin Technologies Limited (Formerly known as M/s. KFin Technologies Private Limited) dated July 6, 2022 confirming the above, is enclosed for your reference. BIOCON LTD. - 532523 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Pursuant to Regulation 30 and 47 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed the copies of newspaper advertisement published on July 06, 2022 in Financial Express (English Language) and Vijayavani (Kannada Language), regarding Notice of the 44th Annual General Meeting, Remote E-Voting facility, cut-off date and Annual Report for the FY 2021-22 of the Company. The above information will also be available on the website of the Company at www.biocon.com.
Biocon arm Syngene ends contract with Bioinnovat Research over graft case
Guljit Sethi of Bioinnovat was named in CBI FIR on a bribery case involving CDSCO official and Biocon Biologics executive BIOCON LTD. - 532523 - Reg. 34 (1) Annual Report.
Annual Report (ESG Report encompassing Business Responsibility and Sustainability Report is a supplement to the Annual Report) of the Company for FY 2021-22 along with Notice of Annual General Meeting. BIOCON LTD. - 532523 - Company Statement
Company Statement titled "Biocon Biologics Receives EU GMP Certification for Its New Biologics Manufacturing Facility in Bengaluru"